Body Pharm NAD+ 1000 Pen

The Body Pharm NAD+ 1000 Pen is a 1000 mg nicotinamide adenine dinucleotide research preparation marketed for in vitro and cellular longevity work. UAE-based laboratories currently source it through international research suppliers such as JCSG rather than a local MOHAP-registered distributor. AED retail pricing is not fixed on the public product page as of 2026; the listing displays a euro figure that converts at the prevailing rate at checkout, so confirm the live AED amount before raising a purchase order.

This guide covers what the NAD+ 1000 Pen is, why researchers use NAD+ in cellular longevity studies, how the pen format compares to vials in UAE conditions, and how to order it through JCSG with proper compliance checks.

For procurement teams running the NAD+ 1000 mg pen UAE buy evaluation, two facts anchor the decision. NAD+ is not named on publicly indexed UAE controlled-substance or precursor lists, so import falls under general unregistered research-chemical rules rather than NAD+-specific restrictions. The supplier's public listing does not include a downloadable certificate of analysis or stated HPLC purity, meaning certificates of analysis (CoAs) must be requested directly from JCSG before purchase.

Key Takeaways

• The Body Pharm NAD+ 1000 Pen is a pre-filled research device for in vitro cellular longevity and mitochondrial bioenergetics work, not for human or veterinary use.
• NAD+ is not listed on MOHAP controlled-substance registers, but import still requires institutional compliance and customs clearance as an unregistered injectable-format material.
• Pen format offers reconstitution-free dosing, better ambient resilience in Gulf heat, and tighter precision than lyophilised vials for UAE laboratory workflows.
• Typical sirtuin and mitochondrial assays operate NAD+ at 50–500 μM, with 100 μM a standard working concentration in 2023–2024 protocols.
• AED pricing converts live at checkout; request batch-specific certificates of analysis, HPLC purity, and endotoxin data directly from JCSG before procurement sign-off.
• Pairing NAD+ with the Body Pharm MOTS-C 32 Pen enables cross-pathway mitochondrial bioenergetics designs in a single experimental block.

What Is the Body Pharm NAD+ 1000 Pen?

The Body Pharm NAD+ 1000 Pen is a pre-filled research device containing 1000 mg of nicotinamide adenine dinucleotide (NAD+), supplied by Body Pharm and listed on JCSG for in vitro and cellular longevity studies. The format eliminates vial reconstitution, delivering the compound in a self-contained pen housing intended for laboratory handling, not clinical administration.

The public JCSG listing does not state whether the device operates as a single-use or multi-dose mechanism, and per-dose volume is similarly absent from the product description. Researchers planning dose-response work should request the technical sheet directly from the supplier before specifying assay volumes.

Classification sits firmly in the research-chemical category: the product is marketed for cellular energy and longevity research, not human or veterinary use. UAE delivery is fulfilled through JCSG's international shipping channels, with no MOHAP-registered local distributor as of 2026.

Where it fits in mitochondrial research programmes

Laboratories building a mitochondrial biology workflow often pair NAD+ preparations with peptides acting on adjacent pathways. The Body Pharm MOTS-C 32 Pen, a mitochondrial-derived peptide studied in metabolic regulation, is commonly evaluated alongside NAD+ substrates; the broader MOTS-C research compounds category lists related preparations.

NAD+ Biology: Why Researchers Study This Coenzyme

NAD+ is a redox coenzyme that shuttles electrons between catabolic and anabolic reactions through the NAD+/NADH cycle, making it indispensable to cellular energy metabolism and enzymatic signalling. In glycolysis, the tricarboxylic acid (TCA) cycle, and fatty-acid β-oxidation, NAD+ accepts hydride to form NADH, which then donates electrons to Complex I of the mitochondrial electron transport chain. The ratio of oxidised to reduced forms acts as a metabolic sensor that constrains flux through hundreds of dehydrogenase reactions.

Three research areas dominate current NAD+ procurement justifications in cellular longevity programmes.

Sirtuin activation and epigenetic regulation

Sirtuins SIRT1 through SIRT7 are NAD+-dependent deacylases that couple metabolic state to chromatin remodelling, transcription factor activity, and mitochondrial protein acetylation. SIRT1 and SIRT3 are the most frequently assayed isoforms in longevity work; SIRT3 localises to the mitochondrial matrix and deacetylates substrates including SOD2 and components of the OXPHOS machinery. SIRT7 has nucleolar functions linked to ribosomal RNA transcription and chromatin compaction. Cell-free sirtuin activity assays in 2023–2024 literature typically run NAD+ at 50–500 μM, with 100 μM a common working concentration for screening deacetylase activators and inhibitors.

Mitochondrial oxidative phosphorylation

NAD+ availability gates Complex I-driven oxidative phosphorylation and, by extension, ATP yield. Intracellular NAD+ declines with age in mammalian tissue and correlates with reduced mitochondrial respiratory capacity. This decline is the mechanistic rationale most often cited in procurement justifications. Foundational work by Verdin (Science, 2015) framed NAD+ as a central node linking metabolism to ageing, and Rajman et al. (Cell Metabolism, 2018) catalogued NAD+ precursor strategies.

PARP-mediated DNA repair

Poly(ADP-ribose) polymerases, principally PARP1, consume NAD+ as substrate when ligating ADP-ribose units onto target proteins at sites of DNA damage. Chronic genotoxic stress drives sustained PARP activation, which competes with sirtuins for the same NAD+ pool. Intracellular NAD+ is regenerated through the salvage pathway, in which NAMPT (nicotinamide phosphoribosyltransferase) catalyses the rate-limiting conversion of nicotinamide to NMN. This substrate competition between PARPs, sirtuins, and NAMPT-driven salvage is the conceptual basis for in vitro experiments examining how NAD+ supplementation modulates the SIRT–PARP balance under oxidative or alkylating challenge.

Sirtuin Activation and Longevity Pathways

Raising intracellular NAD+ shifts the substrate-saturation curve for sirtuin enzymes, increasing deacetylation of targets such as PGC-1α, FOXO3a, and mitochondrial acetyl-proteome substrates implicated in respiratory chain efficiency. This is the mechanistic basis for treating exogenous NAD+ as a controlled variable in caloric-restriction-mimicry models: rather than imposing nutrient deprivation, the researcher manipulates cofactor availability directly and reads out sirtuin-dependent endpoints.

Routine SIRT1 and SIRT3 fluorescence and HPLC-based deacetylase assays in 2023–2024 protocols operate with NAD+ in the 50–500 μM range, with 100 μM a frequently reported working concentration for activator and inhibitor screening. For in vitro designs pairing sirtuin readouts with mitochondrial peptide co-treatments, the Body Pharm MOTS-C 32 Pen is the adjacent compound most often matched to NAD+ arms.

Mitochondrial Function and Cellular Energy Research

NAD+ is the obligate electron acceptor at three TCA cycle steps (isocitrate, α-ketoglutarate, and malate dehydrogenase reactions) and feeds reducing equivalents into Complex I, making it the rate-limiting cofactor in oxidative phosphorylation models. In primary hepatocyte and C2C12 myotube systems, exogenous NAD+ supplementation is the standard manipulation used to interrogate PGC-1α-driven mitochondrial biogenesis, with 2023–2024 protocols reading out citrate synthase activity, mtDNA copy number, and Seahorse OCR endpoints.

The 1000 mg pen format is dimensioned for high-throughput work: at a 100 μM working concentration in a 96-well plate (200 μL per well), a single 1000 mg cartridge supplies cofactor for several thousand wells, supporting factorial designs across donor lines, time points, and co-treatments without inter-lot variation. Pairing NAD+ arms with the Body Pharm MOTS-C 32 Pen lets researchers probe nuclear-encoded and mitochondrial-encoded biogenesis signals in the same experimental block.

Pen Format vs Vial: What UAE Labs Should Know

Pen-format NAD+ has four practical advantages over lyophilised vials for UAE laboratory workflows: zero reconstitution variance, better ambient resilience during last-mile delivery, tighter dose precision, and greater tolerance to brief courier-leg temperature excursions between Dubai and Abu Dhabi distribution hubs. Long-term storage at 2–8 °C remains required for both formats. Pen cartridges also present a smaller surface area for moisture ingress, which reduces the risk of hydrolysis during customs clearance delays, a real concern given how long unregistered injectables can sit at UAE ports.

Reconstitution and dosing variance

Lyophilised NAD+ vials require buffer reconstitution at the bench, introducing operator variance in final molarity, mixing time, and dissolution completeness. The sealed pen cartridge eliminates this step, which matters when running factorial sirtuin assays where 100 μM working concentrations are standard in 2023–2024 protocols. Per-dose volume and dose-count for the Body Pharm NAD+ 1000 Pen are not publicly specified on the product page, so labs should request the technical sheet from the supplier before designing high-throughput plates.

Ambient stability in Gulf conditions

July–August mean maximum temperatures in Dubai and Abu Dhabi sit around 40–43 °C with coastal relative humidity frequently in the 60–70% range, based on multi-year National Centre of Meteorology climatology. Lyophilised cakes are hygroscopic; any seal compromise during a hot courier leg risks moisture ingress and partial hydrolysis before the vial reaches the cold room. Sealed pen cartridges present a smaller exposed surface and a fixed aqueous matrix, which is more forgiving of the 30–90 minute ambient windows typical of UAE domestic courier handoffs.

Cold-chain logistics from UAE hubs

Shipments routed through Dubai South or Khalifa Industrial Zone Abu Dhabi (KIZAD) generally arrive at institutional receiving within 24 hours, but customs clearance for unregistered research-only injectables can extend this. NAD+ is not named in publicly indexed MOHAP controlled-substance or precursor lists as of 2025–2026, so clearance follows general unregistered-injectable rules rather than compound-specific restrictions. Pen format reduces the consequence of a 4–8 hour excursion above 8 °C during this window.

For paired mitochondrial-biogenesis work, the same pen-versus-vial logic applies to the Body Pharm MOTS-C 32 Pen and the broader MOTS-C research compounds category.

Body Pharm as a Research Compound Manufacturer

Body Pharm is a research-grade peptide and small-molecule supplier whose catalogue is distributed through JCSG across European and UAE channels, with product pages presenting compounds in pre-filled pen format rather than lyophilised vials. Public listings position the brand around injection-pen delivery for cellular and longevity research, though the JCSG NAD+ 1000 Pen page does not publish a downloadable certificate of analysis, HPLC purity figure, or batch-release documentation on the open product description. Researchers evaluating supplier credibility should request CoA, residual solvent, and endotoxin data directly before procurement, these are not transparent at the catalogue level.

The brand's UAE catalogue depth is documentable through adjacent pen-format SKUs spanning several mechanistic classes:

• Growth-hormone-axis compounds: Body Pharm Tesamorelin 32 Pen, Body Pharm CJC-1295 with DAC 2
• Incretin research material: Body Pharm Tirzepatide 30 Pen
• Tissue-repair sequences: Body Pharm TB500
• Insulin-mimetic anabolic signalling reagents: Body Pharm IGF-1 LR3
• Mitochondrial-derived peptides: Body Pharm MOTS-C 32 Pen

For laboratories building a mitochondrial bioenergetics workstream pairing NAD+ preparations with mitochondrial peptides, the broader MOTS-C research compounds category sits within the same supplier ecosystem.

Ordering the NAD+ 1000 Pen in the UAE: What to Expect

UAE researchers can order the Body Pharm NAD+ 1000 Pen through the JCSG UAE storefront at jcsg.org/ae, with checkout, tracked shipping to UAE addresses, and order confirmation handled directly through the vendor account. AED pricing is not currently fixed on the public product page, which displays a euro figure subject to conversion at the prevailing 2026 rate; verify the live AED amount at checkout before raising a purchase order. Comparable 1000 mg NAD+ research pens at similar suppliers have historically settled in the AED 800–1,400 band, but the live JCSG figure is the only binding number.

All material listed under this SKU is supplied for in vitro and laboratory research use only and is not intended for human consumption, clinical administration, or veterinary application. Before ordering, confirm your institutional procurement requirements, including any internal chemical-import declarations, ethics-committee notifications, and customs documentation for unregistered injectable-format research materials. NAD+ is not named on published MOHAP controlled lists but still falls under general unregistered-product import rules.

Laboratories consolidating a mitochondrial bioenergetics workstream can add the Body Pharm MOTS-C 32 Pen to the same order, or browse the wider MOTS-C research compounds category to bundle complementary mitochondrial-derived peptides under a single shipment.

Place an order or request a CoA

Add the NAD+ 1000 Pen to cart at jcsg.org/ae, then enquire directly for batch-specific certificate of analysis, HPLC purity, residual solvent, and endotoxin data before procurement sign-off. Quote the SKU and your institutional account reference in the CoA request to speed batch matching.

Related Research Compounds Available in the UAE

Researchers building a cellular-energy or ageing-biology workstream around NAD+ typically evaluate adjacent compound classes: mitochondrial-derived peptides, growth-factor signalling agents, GH-axis modulators, and tissue-repair sequences. Each addresses a distinct node in the metabolic and regenerative research map, and pairing them with NAD+ allows cross-pathway experimental designs without duplicating mechanism.

MOTS-C is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene and studied for its role in AMPK signalling and metabolic homeostasis, making it a direct mechanistic neighbour to NAD+ in mitochondrial bioenergetics research. UAE-based laboratories can source the Body Pharm MOTS-C 32 Pen as a single SKU, or compare formats across the broader MOTS-C research compounds category.

Growth-factor and GH-axis adjuncts

IGF-1 LR3 is a long-arginine analogue of insulin-like growth factor 1 used in receptor-binding and anabolic signalling studies, relevant where researchers are isolating mTOR–NAD+ crosstalk in cell models. Tesamorelin, a growth-hormone-releasing hormone (GHRH) analogue, is studied in metabolic and lipid-handling research and provides an upstream GH-axis comparator to sirtuin-mediated metabolic effects.

Tissue-repair pairing

TB500, a synthetic fragment related to thymosin beta-4, is investigated in tissue-repair and cytoskeletal research, useful where NAD+ depletion models intersect with regeneration assays. These pairings are mechanistic suggestions for in vitro experimental design and do not constitute therapeutic recommendations.

Frequently Asked Questions

The Body Pharm NAD+ 1000 Pen is a research-use NAD+ formulation containing 1000 mg of nicotinamide adenine dinucleotide intended for in vitro and cellular laboratory work, not for human administration. The following answers address the queries UAE researchers most commonly raise before procurement.